BGNE Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Notice: This stock is marked as potentially delisted. It may not be actively trading.

Insider Ownership Percentage: 7.43%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $219,768,883.46

BeiGene Insider Trading History Chart

BeiGene Share Price & Price History

^$0.00

+0.30 (1.20%)

As of 12/31/2024 06:17 PM ET

BeiGene Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/10/2024	Xiaodong Wang	insider	Sell	41,760	$186.90	$7,804,944.00
12/9/2024	Bros. Advisors Lp Baker	Director	Sell	1,037,017	$187.27	$194,202,173.59	791,493
11/26/2024	Xiaodong Wang	insider	Sell	40,468	$190.10	$7,692,966.80
10/8/2024	John Oyler	CEO	Sell	6,175	$232.22	$1,433,958.50
9/30/2024	Chan Henry Lee	SVP	Sell	1,202	$237.10	$284,994.20
9/27/2024	Lai Wang	Insider	Sell	5,000	$220.35	$1,101,750.00	920,920
9/19/2024	Xiaobin Wu	COO	Sell	4,500	$200.14	$900,630.00
9/17/2024	Xiaobin Wu	COO	Sell	500	$200.00	$100,000.00	4,500
9/3/2024	Titus B. Ball	insider	Sell	137	$189.94	$26,021.78
9/3/2024	Xiaobin Wu	COO	Sell	5,556	$189.65	$1,053,695.40
7/30/2024	Chan Henry Lee	SVP	Sell	834	$160.57	$133,915.38
7/1/2024	Julia Aijun Wang	CFO	Sell	472	$143.90	$67,920.80
6/24/2024	John Oyler	CEO	Sell	2,789	$159.58	$445,068.62
6/24/2024	Julia Aijun Wang	CFO	Sell	899	$155.66	$139,938.34
6/24/2024	Lai Wang	insider	Sell	1,064	$159.80	$170,027.20
6/24/2024	Xiaobin Wu	COO	Sell	1,459	$159.79	$233,133.61
4/10/2024	John Oyler	CEO	Sell	26,716	$148.89	$3,977,745.24	12,084
3/12/2024	John Oyler	CEO	Sell	37,668	$164.02	$6,178,305.36	12,332
2/29/2024	Julia Aijun Wang	CFO	Sell	397	$167.08	$66,330.76
7/31/2023	Chan Henry Lee	SVP	Sell	791	$216.26	$171,061.66
7/3/2023	Julia Aijun Wang	CFO	Sell	472	$179.55	$84,747.60
6/26/2023	Lai Wang	insider	Sell	1,108	$181.92	$201,567.36
6/26/2023	Xiaobin Wu	COO	Sell	1,495	$182.37	$272,643.15
6/23/2023	Corazon (Corsee) D. Sanders	Director	Sell	578	$182.32	$105,380.96
6/23/2023	Julia Aijun Wang	CFO	Sell	840	$182.85	$153,594.00
6/20/2023	Lai Wang	insider	Sell	1,325	$192.42	$254,956.50
6/14/2023	Advisors Ltd. Hhlr	Major Shareholder	Sell	273,728	$207.72	$56,858,780.16	142,888,241
6/12/2023	Advisors Ltd. Hhlr	Major Shareholder	Sell	1,250,212	$195.21	$244,053,884.52	144,086,369
6/8/2023	Advisors Ltd. Hhlr	Major Shareholder	Sell	1,163,825	$218.14	$253,876,785.50	145,879,233
6/7/2023	Lai Wang	insider	Sell	462	$224.74	$103,829.88
6/7/2023	Xiaobin Wu	COO	Sell	3,291	$224.73	$739,586.43
5/8/2023	Xiaobin Wu	COO	Sell	7,000	$253.72	$1,776,040.00
3/8/2023	Xiaodong Wang	insider	Sell	67,635	$226.03	$15,287,539.05
1/11/2023	Xiaodong Wang	insider	Sell	2,500	$252.66	$631,650.00	5,512,556
1/10/2023	John Oyler	CEO	Sell	6,797	$248.52	$1,689,190.44
1/9/2023	Xiaodong Wang	insider	Sell	900	$250.00	$225,000.00
12/29/2022	John Oyler	CEO	Sell	1,716	$224.46	$385,173.36
12/27/2022	John Oyler	CEO	Sell	1,120	$224.29	$251,204.80
12/13/2022	Xiaodong Wang	Insider	Sell	3,013	$211.33	$636,737.29	5,577,556
11/15/2022	John Oyler	CEO	Sell	25,000	$206.84	$5,171,000.00
11/15/2022	Xiaodong Wang	Insider	Sell	1,987	$210.14	$417,548.18	5,629,556
9/20/2022	John Oyler	CEO	Sell	30,520	$153.50	$4,684,820.00	2,070,913
7/1/2022	Julia Aijun Wang	CFO	Sell	295	$158.50	$46,757.50
6/27/2022	Lai Wang	insider	Sell	458	$177.32	$81,212.56
6/21/2022	Lai Wang	insider	Sell	723	$149.01	$107,734.23
6/21/2022	Xiaobin Wu	COO	Sell	1,010	$144.36	$145,803.60
6/17/2022	Julia Aijun Wang	CFO	Sell	161	$136.64	$21,999.04
6/17/2022	Lai Wang	Insider	Sell	445	$139.40	$62,033.00	723
6/17/2022	Xiaobin Wu	COO	Sell	578	$139.60	$80,688.80	1,010
6/6/2022	Lai Wang	insider	Sell	660	$142.00	$93,720.00
6/6/2022	Xiaobin Wu	COO	Sell	3,410	$141.99	$484,185.90
5/5/2022	Xiaobin Wu	COO	Sell	6,725	$164.35	$1,105,253.75

See Full Table

SEC Filings (Institutional Ownership Changes) for BeiGene (NASDAQ:BGNE)

48.55% of BeiGene stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

BeiGene Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
12/26/2024	JPMorgan Chase & Co.	9,780	$2.20M	0.0%	-21.7%	0.010%
12/13/2024	Exome Asset Management LLC	15,300	$3.44M	2.3%	-53.9%	0.016%
11/25/2024	Sanctuary Advisors LLC	4,484	$1.01M	0.0%	-33.7%	0.005%
11/15/2024	Public Employees Retirement System of Ohio	11,917	$2.68M	0.0%	-73.2%	0.012%
11/15/2024	MML Investors Services LLC	4,434	$1M	0.0%	-15.3%	0.005%
11/15/2024	XTX Topco Ltd	7,191	$1.61M	0.1%	N/A	0.007%
11/15/2024	Temasek Holdings Private Ltd	2,388,576	$536.26M	2.2%	-20.8%	2.452%
11/15/2024	State Street Corp	2,226	$0.50M	0.0%	-3.2%	0.002%
11/15/2024	Stifel Financial Corp	12,807	$2.88M	0.0%	-25.4%	0.013%
11/15/2024	Quantinno Capital Management LP	1,314	$0.30M	0.0%	N/A	0.001%
11/15/2024	Point72 Asset Management L.P.	667,166	$149.79M	0.4%	+74.9%	0.685%
11/15/2024	Point72 Asia Singapore Pte. Ltd.	300	$67K	0.0%	N/A	0.000%
11/15/2024	Erste Asset Management GmbH	20,500	$4.48M	0.1%	N/A	0.021%
11/14/2024	Bellevue Group AG	58,729	$13.19M	0.2%	+129.2%	0.060%
11/14/2024	Portland Investment Counsel Inc.	3,000	$0.67M	0.2%	+50.0%	0.003%
11/14/2024	Verition Fund Management LLC	1,250	$0.28M	0.0%	N/A	0.001%
11/14/2024	Capstone Investment Advisors LLC	5,311	$1.19M	0.0%	N/A	0.005%
11/14/2024	Walleye Capital LLC	26,721	$6M	0.0%	+50.1%	0.027%
11/14/2024	UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC	3,786	$0.85M	0.0%	-21.2%	0.004%
11/13/2024	BNP Paribas Financial Markets	5,280	$1.19M	0.0%	-9.8%	0.005%
11/13/2024	FMR LLC	1,660,011	$372.69M	0.0%	+0.8%	1.704%
11/13/2024	The Manufacturers Life Insurance Company	57,384	$12.88M	0.0%	+14.2%	0.059%
11/13/2024	DRW Securities LLC	2,553	$0.57M	0.0%	N/A	0.003%
11/12/2024	Citigroup Inc.	26,312	$5.91M	0.0%	+25.9%	0.027%
11/12/2024	Massachusetts Financial Services Co. MA	11,874	$2.67M	0.0%	N/A	0.012%
11/9/2024	Primecap Management Co. CA	4,974,289	$1.12B	0.8%	-0.2%	5.110%
11/8/2024	BNP PARIBAS ASSET MANAGEMENT Holding S.A.	97,895	$21.98M	0.1%	+0.3%	0.101%
11/8/2024	Advisors Asset Management Inc.	280	$63K	0.0%	-43.3%	0.000%
11/8/2024	Connor Clark & Lunn Investment Management Ltd.	225,854	$50.71M	0.2%	+160.0%	0.232%
11/7/2024	LMR Partners LLP	6,838	$1.54M	0.0%	N/A	0.007%
11/6/2024	Oppenheimer Asset Management Inc.	30,427	$6.83M	0.1%	+13.0%	0.031%
11/5/2024	Baillie Gifford & Co.	3,705,756	$831.98M	0.6%	+0.6%	3.807%
11/4/2024	Venturi Wealth Management LLC	1,600	$0.36M	0.0%	-43.3%	0.002%
11/4/2024	Crossmark Global Holdings Inc.	4,829	$1.08M	0.0%	+25.4%	0.005%
11/1/2024	Atria Investments Inc	1,927	$0.43M	0.0%	-25.1%	0.002%
11/1/2024	Assetmark Inc.	17,158	$3.85M	0.0%	-7.8%	0.018%
11/1/2024	XY Capital Ltd	30,464	$6.84M	2.3%	N/A	0.031%
11/1/2024	Fiera Capital Corp	6,011	$1.35M	0.0%	+60.9%	0.006%
10/31/2024	M&G PLC	173,075	$38.94M	0.2%	-3.7%	0.179%
10/30/2024	AlphaCentric Advisors LLC	5,500	$1.24M	0.9%	-63.3%	0.006%
10/30/2024	Asset Management One Co. Ltd.	20,453	$4.59M	0.0%	+14.5%	0.021%
10/29/2024	Van ECK Associates Corp	38,888	$8.60M	0.0%	-59.3%	0.040%
10/25/2024	China Universal Asset Management Co. Ltd.	8,510	$1.91M	0.2%	+69.4%	0.009%
10/25/2024	abrdn plc	27,919	$6.27M	0.0%	-15.6%	0.029%
10/24/2024	PFG Investments LLC	935	$0.21M	0.0%	N/A	0.001%
10/23/2024	Mirae Asset Global Investments Co. Ltd.	3,745	$0.82M	0.0%	-10.3%	0.004%
10/19/2024	Allspring Global Investments Holdings LLC	162	$36K	0.0%	N/A	0.000%
10/18/2024	Raymond James & Associates	14,250	$3.20M	0.0%	-33.0%	0.015%
10/18/2024	Blue Trust Inc.	123	$28K	0.0%	+156.3%	0.000%
10/16/2024	Bleakley Financial Group LLC	4,031	$0.91M	0.0%	-27.2%	0.004%
10/9/2024	LVW Advisors LLC	1,001	$0.23M	0.0%	-49.4%	0.001%
10/3/2024	SG Americas Securities LLC	467	$0.11M	0.0%	N/A	0.000%
9/5/2024	Sanctuary Advisors LLC	6,761	$1.04M	0.0%	N/A	0.007%
8/21/2024	Truist Financial Corp	1,521	$0.22M	0.0%	+10.1%	0.002%
8/16/2024	Driehaus Capital Management LLC	8,185	$1.17M	0.0%	N/A	0.008%
8/15/2024	The Manufacturers Life Insurance Company	50,262	$7.17M	0.0%	+8.4%	0.052%
8/15/2024	Affinity Asset Advisors LLC	110,000	$15.69M	1.8%	+33.9%	0.114%
8/14/2024	Squarepoint Ops LLC	72,055	$10.28M	0.0%	+2.5%	0.074%
8/14/2024	Point72 Asset Management L.P.	381,382	$54.41M	0.1%	N/A	0.393%
8/14/2024	Marshall Wace LLP	51,987	$7.42M	0.0%	-50.2%	0.054%
8/14/2024	ProShare Advisors LLC	2,639	$0.38M	0.0%	-9.1%	0.003%
8/14/2024	Profund Advisors LLC	4,780	$0.68M	0.0%	-19.8%	0.005%
8/13/2024	Sei Investments Co.	24,248	$3.46M	0.0%	+3.6%	0.025%
8/12/2024	Hsbc Holdings PLC	24,181	$3.45M	0.0%	-36.7%	0.025%
8/9/2024	Primecap Management Co. CA	4,986,289	$711.39M	0.5%	-0.3%	5.146%
8/9/2024	Dimensional Fund Advisors LP	11,499	$1.65M	0.0%	+118.9%	0.012%
8/8/2024	Envestnet Asset Management Inc.	63,140	$9.01M	0.0%	-2.5%	0.065%
8/8/2024	Oppenheimer Asset Management Inc.	26,924	$3.84M	0.0%	+48.6%	0.028%
8/8/2024	NINE MASTS CAPITAL Ltd	1,700	$0.24M	0.1%	-17.1%	0.002%
8/8/2024	Barings LLC	51,763	$7.39M	0.2%	+66.4%	0.053%
8/7/2024	Headlands Technologies LLC	2,773	$0.40M	0.0%	+761.2%	0.003%
8/6/2024	Acadian Asset Management LLC	947	$0.14M	0.0%	-25.1%	0.001%
8/3/2024	TD Asset Management Inc	114,378	$16.32M	0.0%	+1.4%	0.118%
8/1/2024	Fiera Capital Corp	3,736	$0.53M	0.0%	+45.9%	0.004%
8/1/2024	Rhumbline Advisers	1,951	$0.28M	0.0%	-7.1%	0.002%
7/31/2024	Van ECK Associates Corp	95,577	$13.64M	0.0%	+8.9%	0.099%
7/30/2024	BNP PARIBAS ASSET MANAGEMENT Holding S.A.	97,629	$13.93M	0.0%	-0.5%	0.101%
7/29/2024	Crossmark Global Holdings Inc.	3,852	$0.55M	0.0%	-11.4%	0.004%
7/26/2024	Bank of New York Mellon Corp	5,299	$0.76M	0.0%	-1.8%	0.005%
7/26/2024	AlphaCentric Advisors LLC	15,000	$2.14M	1.6%	-10.4%	0.015%
7/26/2024	EFG Asset Management North America Corp.	17,780	$2.54M	0.4%	+21.7%	0.018%
7/25/2024	Baillie Gifford & Co.	3,681,949	$525.30M	0.4%	-1.3%	3.797%
7/20/2024	China Universal Asset Management Co. Ltd.	5,024	$0.72M	0.1%	-37.1%	0.005%
7/19/2024	Raymond James & Associates	21,275	$3.04M	0.0%	+0.4%	0.022%
7/16/2024	M&G Plc	179,779	$25.71M	0.2%	-5.4%	0.185%
7/10/2024	Simplicity Wealth LLC	5,526	$0.79M	0.0%	-2.3%	0.006%
5/21/2024	Swedbank AB	16,599	$2.60M	0.0%	N/A	0.017%
5/17/2024	Artal Group S.A.	404,782	$63.30M	1.6%	+0.1%	0.423%
5/15/2024	Bellevue Group AG	24,929	$3.90M	0.1%	-12.8%	0.026%
5/15/2024	Price T Rowe Associates Inc. MD	2,026,094	$316.86M	0.0%	+6.2%	2.117%
5/15/2024	Affinity Asset Advisors LLC	82,143	$12.85M	1.6%	N/A	0.086%
5/14/2024	Capital International Sarl	191,942	$30.02M	1.0%	+8.8%	0.201%
5/14/2024	Capital International Ltd. CA	74,874	$11.71M	0.6%	+14.0%	0.078%
5/14/2024	Capital International Inc. CA	858,364	$134.24M	1.8%	+6.0%	0.897%
5/14/2024	Capital International Investors	7,064,428	$1.10B	0.2%	+11.5%	7.383%
5/14/2024	Capital Group Private Client Services Inc.	208,800	$32.65M	0.3%	+5.9%	0.218%
5/14/2024	Capital Group Investment Management PTE. LTD.	16,030	$2.51M	0.4%	+14.4%	0.017%
5/14/2024	Nan Fung Group Holdings Ltd	23,022	$3.60M	3.3%	+91.5%	0.024%
5/14/2024	Advisors Asset Management Inc.	643	$0.10M	0.0%	-25.0%	0.001%
5/14/2024	CANADA LIFE ASSURANCE Co	28,304	$4.42M	0.0%	+4.7%	0.030%

Data available starting January 2016

See Full Table

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC. The company is also developing inhibitors comprising Sonrotoclax (BGB-11417), BGB-10188, BGB-21447, Ociperlimab (BGB-A1217), Surzebiclimab (BGB-A425), BGB-15025, BGB-26808, Lifirafenib (BGB-283), BGB-3245, BGB-30813, and BGB-43395; antibodies, including Zanidatamab, BGB-A445, and BGB-A3055, as well as BGB-16673, a BTK-targeted CDAC, and BGB-24714, a SMAC mimetic. It has collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, Bristol Myers Squibb company, Shandong Luye Pharmaceutical Co., Ltd., Nanjing Leads Biolabs, Inc., EUSA Pharma, Assembly Biosciences, Inc., Bio-Thera Solutions, Ltd., and Nanjing Leads Biolabs Co., Ltd. The company was incorporated in 2010 and is based in Grand Cayman, the Cayman Islands.

Today's Range

Now: N/A

50 Day Range

MA: $194.32

$174.72

$217.22

52 Week Range

Now: N/A

Volume

331,608 shs

Average Volume

283,704 shs

Market Capitalization

$18.03 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.57

Who are the company insiders with the largest holdings of BeiGene?: BeiGene's top insider investors include:
Advisors Ltd Hhlr (Major Shareholder)
Lai Wang (Insider)
Bros Advisors Lp Baker (Director)
John Oyler (CEO)
Xiaobin Wu (COO)
Chan Henry Lee (SVP)
Corazon (Corsee) D Sanders (Director)
Julia Aijun Wang (CFO)
Titus B Ball (Insider)
Xiaodong Wang (Insider)
Learn More about top insider investors at BeiGene.